Russia approves the third COVID-19 vaccine’Kobibak’

Input 2021.02.20 17:52

On the 20th (local time), Russia officially approved the third novel coronavirus (Corona 19) vaccine,’Kobibak’, which it developed itself, Tas News reported.

Russia’s Prime Minister Mikhail Mischstein said at the meeting on the vaccine that the approval of Kobivac was announced on the day, and said that the first production of Kobivac will be 120,000 doses (one dose) in the market in the middle of next month. Prime Minister Mischstein said, “Russia is the only country to have developed three types of COVID-19 vaccines to date.”

Health Minister Mikhail Murashko also explained to reporters that Kobebak proved efficacy and safety in a clinical trial for volunteers. He introduced that even after approval, it will carry out a phase 3 clinical trial (phase 3) and supply it to the market at the same time.

Kobivac is an inactivated vaccine developed by the Chumakov Immunology Research and Development Center under the Russian Academy of Sciences. Inactivated vaccines are a traditional vaccine manufacturing method that produces antibodies in the body by injecting a virus whose replication capacity has been removed. Idar Ishmukhametov, director of the Chumakov Center, explained, “Because Kobibak uses the whole virus, not a piece of genetic information, it is also effective for mutant viruses.”

The Kobivac vaccine, which entered the first phase in October last year, is said to have almost finished phase 2. Like the two vaccines developed earlier in Russia, approval was achieved before phase 3 and after phases 1 and 2. Even after approval, the center plans to proceed with the third phase for 3,000 volunteers.

Russia previously approved the world’s first COVID-19 vaccine’Sputnik V’developed by the Gamalea National Center for Infectious Diseases and Microbiology under its Ministry of Health in August last year. However, the approval immediately after phases 1 and 2 raised controversy over the efficacy and safety of the vaccine. In October last year, the’Epibakcorona’ vaccine developed by Vector, the National Virus and Biotechnology Research Center under the Consumer Rights Protection and Welfare Supervisory Service (Rosport Revnadzor), a local health, hygiene and quarantine authority, was approved for the second time. Received. It was also approved after phase two.